Kerscher M. Effects of an oral contraceptive containing chlormadinone acetate and ethinylestradiol on hair and skin quality in women wishing to use hormonal contraception. J Eur Acad Dermatol Venereol 2013; 27 (5): 601-8.Аганезова Н.В., Аганезов С.С. Комбинированные оральные контрацептивы: не только контрацепция. Акуш. и гинекол. 2015; 6: 118-23Reid R.L, Westhoff C, Mansour D et al. Oral contraceptives and venous thromboembolism. Consensus opinion from an international workshop held in Berlin, Germany in December 2009. J Fam Plann Reprod Health Care 2010; 36: 117-22.Прилепская В.Н., Межевитинова Е.А., Куземин А.А. Контрацепция и гиперандрогения. Клинические эффекты препарата, содержащего хлормадинона ацетат. Гинекология. 2015; 17 (4): 4-8.Oral contraceptive containing chlormadinone acetate and ethinylestradiol reduces plasma concentrations of matrix metalloproteinase-2 in women with polycystic ovary syndrome. Gomes VA Basic Clin Pharmacol Toxicol 2012; 111 (3): 211-6.Zahradnik H.P, Hanjalic-Beck. Ecacy, safety and sustainability of treatment continuation and results of an oral contraceptive containingmcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage - an open-label, prospective, noncontrolled, oce-based Phase III study. Contraception 2008; 77 (5): 337-43.Jaisamrarn U, Santibenchakul S. A comparison of combined oral contraceptives containing chlormadinone acetate versus drospirenone for the treatment of acne and dysmenorrhea: a randomized trial. Contracept Reprod Med 2018; 3: 5.Plewig G, Cunliffe W.J, Binder N et al. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled phase III trial. Contraception 2009; 80 (1): 25-33.Зильберберг Н.В., Толстая А.И. Оценка эффективности и безопасности препарата Белара в комплексной терапии больных акне. Фарматека. 2015; с. 40-5Anthuber S, Schramm G.A, Heskamp M.L. Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study. Clin Drug Invest 2010; 30 (4): 211-20.